<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Bristol Myers Squibb & Co (NYSE: BMY) has posted Q3 revenues of $11.6 billion, an increase of 10%, in line with the consensus estimate of $11.58 billion. Sales growth was driven by Revlimid (+11%), Eliquis (+15%), Opdivo (+7%), and a new product portfolio.
...read full article on Benzinga
